KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other financing activities (2016)

Historic Other financing activities for Jazz Pharmaceuticals (JAZZ) over the last 5 years, with Q3 2016 value amounting to -$3.5 million.

  • Jazz Pharmaceuticals' Other financing activities fell 99468.75% to -$3.5 million in Q3 2016 from the same period last year, while for Sep 2016 it was $320000.0, marking a year-over-year increase of 11252.94%. This contributed to the annual value of $1.8 million for FY2014, which is N/A changed from last year.
  • As of Q3 2016, Jazz Pharmaceuticals' Other financing activities stood at -$3.5 million, which was down 99468.75% from -$4.4 million recorded in Q2 2016.
  • In the past 5 years, Jazz Pharmaceuticals' Other financing activities ranged from a high of $10.6 million in Q1 2015 and a low of -$10.6 million during Q2 2015
  • Moreover, its 5-year median value for Other financing activities was $320000.0 (2015), whereas its average is $741000.0.
  • Its Other financing activities has fluctuated over the past 5 years, first skyrocketed by 390365.85% in 2014, then plummeted by 99468.75% in 2016.
  • Over the past 5 years, Jazz Pharmaceuticals' Other financing activities (Quarter) stood at $5.5 million in 2012, then plummeted by 98.51% to $82000.0 in 2013, then tumbled by 2824.39% to -$2.2 million in 2014, then surged by 114.32% to $320000.0 in 2015, then plummeted by 1194.69% to -$3.5 million in 2016.
  • Its last three reported values are -$3.5 million in Q3 2016, -$4.4 million for Q2 2016, and $7.9 million during Q1 2016.